Articles related to Pediatric Hematology/Oncology

Among 90 pediatric patients with relapsed or refractory B-cell precursor ALL, prior blinatumomab was associated with more relapses at atypical extramedullary sites. The retrospective single-center findings require prospective confirmation.

The FDA expanded approval of the CRISPR-based gene therapy Casgevy to include patients as young as 2 years with sickle cell disease or transfusion-dependent beta thalassemia. The decision was supported by pediatric phase 3 data demonstrating sustained reductions in disease burden.

FcγRIII-mediated macrophage phagocytosis emerges as the dominant mechanism of platelet destruction in FNAIT, suggesting targeted receptor blockade could offer a future therapeutic approach, though evidence remains preclinical.

A first joint EULAR/PReS guideline unifies systemic juvenile idiopathic arthritis and adult-onset Still’s disease under a single name, Still’s disease, and recommends early IL-1 or IL-6 inhibitor therapy over prolonged glucocorticoid use.

A retrospective cohort of 146 adult patients with T-cell ALL treated with a pediatric-inspired regimen at a single center achieved 3-year overall survival of 73% and leukemia-free survival of 77%, with age over 60 emerging as the primary adverse prognostic factor and early T-cell precursor phenotype showing no independent survival impact.

A retrospective quasi-experimental study at St. Jude Children’s Research Hospital found that discontinuing empiric antibiotics within 72 hours of febrile neutropenia onset in clinically stable pediatric haploidentical HCT recipients reduced antibiotic exposure by a median of 8 days without significant differences in bloodstream infection, ICU admission, or mortality.